Literature DB >> 23786565

Sumatriptan : treatment across the full spectrum of migraine.

Stephen D Silberstein1, Dawn A Marcus.   

Abstract

INTRODUCTION: Triptans are the first-line treatment for moderate-to-severe migraine headaches. Sumatriptan , the first triptan, is available in different formulations, including subcutaneous (SQ), intranasal, transdermal, oral, and suppository options. AREAS COVERED: Sumatriptan formulations have different pharmacokinetic, efficacy, and adverse event profiles. The fastest and most complete migraine relief occurs with SQ dosing; a needle-free option is available for patients fearful of injections. Oral administration is generally preferred by patients, although variability with absorption limits efficacy, especially for more severe attacks. Intranasal, transdermal, and suppository formulations are options for patients with nausea who do not require or prefer to avoid SQ administration. Transdermal treatment may be limited in some cases by skin irritation. EXPERT OPINION: Patients should use an attack-based treatment approach for their migraine attacks to balance the speed of relief, efficacy, and tolerability. Different sumatriptan formulations allow its use as both first-line and rescue therapies, with additional treatment if needed. This article develops a treatment algorithm that offers suggested roles for different formulations of sumatriptan based on attack severity and response to initial sumatriptan therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23786565     DOI: 10.1517/14656566.2013.810209

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  6 in total

1.  Protective Roles of N-acetyl Cysteine and/or Taurine against Sumatriptan-Induced Hepatotoxicity.

Authors:  Javad Khalili Fard; Hossein Hamzeiy; Mohammadreza Sattari; Mohammad Ali Eghbal
Journal:  Adv Pharm Bull       Date:  2016-12-22

2.  5-Alkyloxytryptamines are membrane-targeting, broad-spectrum antibiotics.

Authors:  Katherine C Faulkner; Katherine A Hurley; Douglas B Weibel
Journal:  Bioorg Med Chem Lett       Date:  2016-10-05       Impact factor: 2.823

3.  A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study).

Authors:  Roger K Cady; Peter J McAllister; Egilius L H Spierings; John Messina; Jennifer Carothers; Per G Djupesland; Ramy A Mahmoud
Journal:  Headache       Date:  2014-10-30       Impact factor: 5.887

4.  A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine.

Authors:  Sagar Munjal; Elimor Brand-Schieber; Kent Allenby; Egilius L H Spierings; Roger K Cady; Alan M Rapoport
Journal:  J Headache Pain       Date:  2017-03-01       Impact factor: 7.277

Review 5.  Breath-powered sumatriptan dry nasal powder: an intranasal medication delivery system for acute treatment of migraine.

Authors:  Stewart J Tepper; Merrilee R Johnstone
Journal:  Med Devices (Auckl)       Date:  2018-05-03

6.  A Pre-Existing Myogenic Temporomandibular Disorder Increases Trigeminal Calcitonin Gene-Related Peptide and Enhances Nitroglycerin-Induced Hypersensitivity in Mice.

Authors:  Hui Shu; Sufang Liu; Yuanyuan Tang; Brian L Schmidt; John C Dolan; Larry L Bellinger; Phillip R Kramer; Steven D Bender; Feng Tao
Journal:  Int J Mol Sci       Date:  2020-06-05       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.